Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients	Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast carcinoma, breast disorder, breast neoplasm, neoplasm, skin disorder	Active, not recruiting	Phase 2	2026-04-13		NCT03650894

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Bristol-Myers Squibb	422
Memorial Sloan Kettering Cancer Center	753
Providence Health & Services	35

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Memorial Sloan Kettering Cancer Center	New York	United States	1000
Providence Oncology & Hematology Care Clinic - Eastside	Portland	United States	2